Compare The Coca-Cola Co K (KO) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs Moderna, Inc. — how do they compare? The Coca-Cola Co K trades at $81.9 (market cap $353.32B), while Moderna, Inc. trades at $60.04 (market cap $23.60B). The key difference: The Coca-Cola Co K is far larger — about 15× Moderna, Inc.'s market cap, and The Coca-Cola Co K pays a 2.58% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| KO | MRNA | |
|---|---|---|
Market Cap | $353.32B | $23.60B |
Volume | 14,630,257 | — |
Sector | Consumer Staples | Health |
52-Week High | $84.92 | $81.80 |
52-Week Low | $65.67 | $22.36 |
Enterprise Value | $383.39B | $19.70B |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $81.56, down 3.96% on the day, with a bearish technical signal but strong fundamentals including a 27.8% net income margin and consistent earnings beats. Recent news highlights institutional accumulation and steady dividend payments. The stock is supported by robust cash flow and brand strength, though near-term price action shows weakness below key resistance.
Outlook remains positive with a consensus price target of $90.67, offering ~11% upside. Risks include regional demand divergence and high debt levels. The stock presents a value opportunity for dividend-focused investors given its 64-year dividend growth streak, but macroeconomic pressures warrant caution.
Moderna (MRNA) trades at $60.47, down 2.18% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported a net loss of -$2.82B in 2025, with revenue declining to $1.92B, though it has beaten EPS estimates in recent quarters. Recent news highlights progress in its cancer pipeline, including a Phase 1 study for mRNA-4200, and an EU contract for its RSV vaccine.
The outlook remains speculative with high execution risk as Moderna transitions beyond COVID-19 vaccines. While pipeline advancements offer long-term potential, persistent losses and negative margins pose significant challenges. Analyst consensus is cautious with a $49 price target, suggesting limited near-term upside amid ongoing fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
